Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

Wed, September 23, 2026 at 5:14 PM GMT+3 2 min read

• LNTH -0.03%

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for "Global Equity Strategy". The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% during the quarter, compared to a 13.90% return for the MSCI World Index, gross dividends reinvested. The Composite remained ahead for the year-to-date period through June 30, 2026, gaining 19.95% versus 9.94% for the benchmark, driven by strong performance from IT holdings, particularly AI-related companies and memory semiconductor suppliers. Please review the Fund's top five holdings to gain insights into its key selections for 2026.

In its second-quarter 2026 investor letter, Polaris Global Equity Strategy highlighted Lantheus Holdings, Inc. (NASDAQ:LNTH). Lantheus Holdings, Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products for clinicians in diagnosis and treatment of heart, cancer, and other diseases. On September 22, 2026, Lantheus Holdings, Inc. (NASDAQ:LNTH) closed at $100.28 per share. Over the past month, Lantheus Holdings, Inc. (NASDAQ:LNTH) declined 0.58%, and its shares gained 92.62% over the past 52 weeks. Lantheus Holdings, Inc. (NASDAQ:LNTH) has a market capitalization of $6.55 billion, and its stock has traded within a 52-week range of $49.67 and $111.86.

Polaris Global Equity Strategy stated the following regarding Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q2 2026 investor letter:

"The Composite markedly outperformed in health care, with five holdings posting double-digit gains. Lantheus Holdings, Inc. (NASDAQ:LNTH) advanced on multiple fronts - strong quarterly earnings, the FDA approval of PYLARIFY TruVu cementing its radiopharmaceutical diagnostics leadership, and intensified M&A interest via a potential $7 billion takeover bid from PE-backed Curium Pharma."

Lantheus Holdings, Inc. (NASDAQ:LNTH) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Lantheus Holdings, Inc. (NASDAQ:LNTH) at the end of the second quarter which was 31 in the previous quarter. While we acknowledge the potential of Lantheus Holdings, Inc. (NASDAQ:LNTH) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.